- Home
- PLSE vs IMTX Comparison
PLSE vs IMTX Comparison
Compare PLSE & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSE | IMTX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | PLSE | IMTX |
|---|---|---|
| Price | $23.05 | $11.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $22.00 | $19.00 |
| AVG Volume (30 Days) | 242.1K | ★ 332.1K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $840.00 | N/A |
| Revenue Next Year | $287.54 | $25.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $4.93 |
| 52 Week High | $26.30 | $12.41 |
Technical Indicators
Market Signals| Indicator | PLSE | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.24 | 56.51 |
| Support Level | $13.40 | $8.97 |
| Resistance Level | $23.89 | $11.41 |
| Average True Range (ATR) | 1.40 | 0.52 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 76.14 | 58.55 |
Price Performance
Historical ComparisonAbout PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.